Skip to content
10-Q

Quarterly Report

VERVE THERAPEUTICS, INC.

0000950170-24-055069

← back to feed
Filed
May 8, 2024 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2024 · May 2, 2024 83.97M sh
Current Liabilities Q1 2024 · Mar 31, 2024 $31.29M
Current Liabilities Q1 2024 · Dec 31, 2023 $37.01M
Total Liabilities Q1 2024 · Mar 31, 2024 $149.29M
Total Liabilities Q1 2024 · Dec 31, 2023 $153.19M
Current Assets Q1 2024 · Mar 31, 2024 $620.33M
Current Assets Q1 2024 · Dec 31, 2023 $637.95M
Total Assets Q1 2024 · Mar 31, 2024 $732.36M
Total Assets Q1 2024 · Dec 31, 2023 $752.69M
Cash And Equivalents Q1 2024 · Dec 31, 2023 $206.18M
Cash And Equivalents Q1 2024 · Mar 31, 2023 $83.75M
Shares Diluted Q1 2024 · Mar 31, 2023 61.79M sh
Capex Q1 2024 · Mar 31, 2023 $3.38M
Operating Cash Flow Q1 2024 · Mar 31, 2023 −$49.1M
Stockholders Equity Q1 2024 · Mar 31, 2023 $509.48M
Stockholders Equity Q1 2024 · Dec 31, 2022 $550.93M
Eps Diluted Q1 2024 · Mar 31, 2023 −$0.84
Eps Basic Q1 2024 · Mar 31, 2023 −$0.84
Sga Expense Q1 2024 · Mar 31, 2023 $12.55M
Rd Expense Q1 2024 · Mar 31, 2023 $47.11M
Net Income Q1 2024 · Mar 31, 2023 −$51.98M
Operating Income Q1 2024 · Mar 31, 2023 −$58.26M